Pascolizumab is a humanized monoclonal antibody for the treatment of asthma. A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 2001/2002.
- ^ Hart, TK; Blackburn, MN; Brigham-Burke, M; Dede, K; Al-Mahdi, N; Zia-Amirhosseini, P; Cook, RM (2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and experimental immunology 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
- ^ ClinicalTrials.gov